Tivozanib (AV-951): Potent Pan-VEGFR Inhibitor for Cancer Therapy

Executive Summary: Tivozanib (AV-951) is a quinoline-urea derivative that selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with an IC₅₀ of 160 pM for VEGFR-2, surpassing the potency of other tyrosine kinase inhibitors (TKIs) such as sunitinib (Schwartz 2022, https://doi.org/10.13028/wced-4a32). It demonstrates minimal off-target activity, including low inhibition of c-KIT, and inhibits PDGFRβ and c-KIT phosphorylation at nanomolar concentrations. Tivozanib achieves substantial antitumor efficacy in renal cell carcinoma (RCC) xenograft models and in clinical settings, yields a median progression-free survival (PFS) of 12.7 months in metastatic RCC. The compound is highly soluble in DMSO (≥22.75 mg/mL) and ethanol (≥2.68 mg/mL with warming), but insoluble in water, and is best stored at -20°C. Tivozanib is distributed by APExBIO under SKU A2251 (product page).

Biological Rationale

Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Vascular endothelial growth factor receptor (VEGFR) signaling is a primary driver of angiogenesis in solid tumors. Inhibiting VEGFR pathways blocks nutrient supply to tumors and is a validated anti-cancer strategy. Tivozanib (AV-951) is designed to provide maximal inhibition of VEGFR-1, VEGFR-2, and VEGFR-3 with high selectivity. Its low off-target profile reduces adverse effects often observed with first-generation TKIs. Such selectivity is crucial for in vitro drug response studies and translational cancer research (Schwartz 2022).

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a second-generation tyrosine kinase inhibitor. It binds competitively to the ATP-binding pocket of VEGFR-1, VEGFR-2, and VEGFR-3, blocking receptor phosphorylation and downstream signaling. The compound demonstrates an IC₅₀ of 160 pM against VEGFR-2 and nanomolar inhibition of PDGFRβ and c-KIT in cellular assays. It does not significantly inhibit other related kinases at pharmacologically relevant concentrations. This high selectivity minimizes off-target toxicity. In tumor models, Tivozanib reduces microvessel density and suppresses tumor growth. Its oral bioavailability enables convenient dosing in clinical and research settings. When combined with EGFR-targeted agents, Tivozanib enhances cell growth inhibition and apoptosis in ovarian carcinoma lines (Schwartz 2022).

Evidence & Benchmarks

• Tivozanib exhibits an IC₅₀ of 160 pM against VEGFR-2, outperforming sunitinib, sorafenib, and pazopanib in potency assays (https://doi.org/10.13028/wced-4a32).
• Minimal inhibition of c-KIT and other kinases is observed at concentrations up to 10 μM in in vitro kinase panels (https://doi.org/10.13028/wced-4a32).
• In RCC xenograft models, Tivozanib significantly decreases tumor volume and vascularization compared to vehicle controls (https://doi.org/10.13028/wced-4a32).
• Clinically, oral Tivozanib (1.5 mg daily, 3 weeks on/1 week off) achieves a median PFS of 12.7 months in metastatic RCC patients (https://doi.org/10.13028/wced-4a32).
• In combination with EGFR inhibitors, Tivozanib demonstrates synergistic inhibition of cell proliferation and induction of apoptosis in ovarian carcinoma cell lines (https://doi.org/10.13028/wced-4a32).

For a deeper mechanistic discussion, see this article, which explores Tivozanib's translational strategies; the current article provides an updated benchmark and workflow integration for preclinical use.

Applications, Limits & Misconceptions

Tivozanib is widely used in oncology research as a reference pan-VEGFR inhibitor. It is suitable for in vitro cell viability, proliferation, and apoptosis assays, as well as in vivo xenograft and angiogenesis models. Its high selectivity enables mechanistic studies of VEGFR signaling without confounding off-target effects. Clinically, Tivozanib is approved for the treatment of renal cell carcinoma. In preclinical studies, it is used to benchmark new anti-angiogenic compounds and in combination regimens with EGFR or other pathway inhibitors.

This article extends the discussion in "Tivozanib: Redefining VEGFR Inhibition in Translational Oncology" by providing structured experimental parameters and highlighting updated clinical benchmarks.

Common Pitfalls or Misconceptions

• Water Solubility: Tivozanib is insoluble in water; use DMSO or ethanol with warming for stock solutions (≥22.75 mg/mL in DMSO).
• Storage Stability: Stock solutions are not stable for long-term storage; prepare fresh aliquots and store at -20°C.
• Off-Target Effects: Despite high selectivity, high concentrations (>10 μM) may inhibit kinases beyond VEGFR family.
• Dosage Misuse: In vitro concentrations above 10 μM do not increase efficacy and may introduce artifacts.
• Clinical Scope: Tivozanib is indicated primarily for renal cell carcinoma; evidence in other tumor types is limited or investigational.

For details on advanced microenvironment modeling applications, see this article, which focuses on angiogenesis modeling—here, we emphasize practical integration and selectivity benchmarking.

Workflow Integration & Parameters

For in vitro cell-based experiments, Tivozanib is typically used at 10 μM for 48 hours to assess cell growth inhibition and apoptosis. Solutions are prepared in DMSO or ethanol (with gentle warming for ethanol). Avoid water as a solvent due to insolubility. For in vivo studies, dosing regimens are adjusted per animal model and research goal; refer to published protocols for RCC xenografts. Clinical administration is 1.5 mg orally, once daily, in a 3-weeks-on, 1-week-off cycle. Store solid compound at -20°C and protect from light and moisture. For detailed experimental workflows and troubleshooting, see this advanced protocol guide; the present article clarifies dosing and storage boundaries.

For procurement and technical support, Tivozanib (AV-951) is available from APExBIO as the A2251 kit (product page).

Conclusion & Outlook

Tivozanib (AV-951) is a reference pan-VEGFR inhibitor for cancer research and clinical use, offering picomolar potency and high selectivity. It surpasses earlier TKIs in efficacy and safety for VEGFR-driven cancers, especially renal cell carcinoma. Its favorable pharmacokinetic and safety profile, along with proven synergy with EGFR inhibitors, positions Tivozanib as a foundational tool in anti-angiogenic therapy development. Continued research will clarify its broader applications and inform rational drug combinations. For further reading on its role in translational research, see this detailed review, which this article updates with new clinical and workflow data.